Chapter III: Clinical Pearls
Watch as the multidisciplinary faculty panel, consisting of Dr. George Bakris, Dr. Robert Eckel, and Dr. Stephen Wiviott have a lively discussion about the application of SGLT-2 inhibitors to clinical practice, including:
- For what patients are they most appropriate?
- Are SGLT-2is and GLP-1 RAs exclusive, or can they be used together?
- How to address some of the potential concerns that limit the uptake of SGLT-2 inhibitors across specialties, including among cardiologists and nephrologists.
- What is the eGFR cutoff for SGLT-2is?
- How do SGLT-2is fit in with existing therapies that reduce cardiorenal risk, such as ACE inhibitors and ARBs?